Kura Oncology's Upcoming Financial Results Announcement
Kura Oncology, Inc. (Nasdaq: KURA), a pioneering biopharmaceutical company focused on precision medicines for cancer treatment, is gearing up to report its second quarter financial results. The announcement is scheduled to take place after the close of U.S. financial markets on a Thursday in early August. Following the report release, Kura’s management will host a comprehensive webcast and conference call to discuss the results and provide essential insights into the company’s progress.
Details of the Webcast and Conference Call
The live conference call will commence at 4:30 p.m. Eastern Time (ET), which is 1:30 p.m. Pacific Time (PT). Interested participants can join the call by dialing the appropriate phone numbers: (800) 579-2543 for U.S. callers and (785) 424-1789 for international participants. When prompted, attendees will need to enter the conference ID: KURAQ2. If you miss the live session, a recording will be accessible through Kura's investor relations page, allowing stakeholders to stay updated on the developments.
Company Overview of Kura Oncology
Kura Oncology is devoted to the advancement of precision cancer medicines, with its pipeline highlighting innovative small molecule therapy candidates. A significant part of its portfolio includes Ziftomenib, which is recognized as the first investigational treatment to obtain Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for acute myeloid leukemia (AML) characterized by relapsed or refractory NPM1 mutations. This designation underlines the therapy's potential and the company's commitment to addressing urgent medical needs in oncology.
Key Partnerships and Collaborations
In a promising move for its future, Kura has established a global strategic collaboration agreement with Kyowa Kirin, targeting the development and commercialization of Ziftomenib for AML and other related malignancies. This partnership aims to facilitate rapid progress in clinical trials and the expansion of treatment options for patients suffering from these conditions.
Clinical Trials and Developments
The companies involved in this collaboration have recently completed enrollment in KOMET-001, a Phase 2 trial aimed at evaluating Ziftomenib in relapsed or refractory NPM1-m AML. Excitingly, in the second quarter of 2025, they announced that the FDA accepted a New Drug Application for Ziftomenib, promising to streamline the path towards making this vital therapy available for adult patients. The anticipated target action date for the Prescription Drug User Fee Act is set for late November 2025, showcasing positive momentum ahead.
Innovative Drug Candidates in Development
Meanwhile, Kura's research is not limited to Ziftomenib alone. The company is actively conducting clinical trials for other promising drug candidates. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is currently under evaluation in a Phase 1 dose-escalation trial as both monotherapy and in combination with targeted therapies for various solid tumors. In addition, Tipifarnib, another potent FTI, is undergoing a Phase 1/2 trial in combination with a targeted drug for patients with PIK3CA-dependent head and neck squamous cell carcinoma.
Connection with Investors and Media
For investors and media inquiries, Kura Oncology maintains open lines of communication through their investor relations team. Contact Greg Mann at 858-987-4046 for any questions or further information regarding the company’s financial disclosures or upcoming events.
Frequently Asked Questions
What is Kura Oncology's primary focus?
Kura Oncology is primarily focused on developing precision medicines for the treatment of cancer, utilizing innovative small molecule drug candidates.
When will Kura Oncology report its Q2 2025 financial results?
Kura Oncology is scheduled to report its second quarter financial results on a Thursday in early August 2025.
How can I access the conference call?
The conference call can be accessed by calling (800) 579-2543 for domestic callers and (785) 424-1789 for international participants. The conference ID is KURAQ2.
What recognition has Ziftomenib received from the FDA?
Ziftomenib has received Breakthrough Therapy Designation from the FDA, indicating its potential to address significant unmet medical needs in AML.
Who can I contact for media inquiries?
For media inquiries, you can reach out to Greg Mann at 858-987-4046.
